Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of sulfalene/pyrimethamine/amodiaquine versus artemether/lumefantrine for malaria treatment
PACTR201508001193368Completed
- Sponsor
- Pfizer
- Start
- Nov 2005
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Trial of artemether, lumefantrine, amodiaquine, sulfamethoxypyrazine and pyrimethamine in malaria and Malaria (2 arms), sponsored by Pfizer. Primary endpoint: Clinical and parasitological cure. Started Nov 2005; status: completed.
02
Drugs
artemetherlumefantrineamodiaquinesulfamethoxypyrazinepyrimethamine
03
Conditions
malariaMalaria
Beyond the preview
Go deeper on PACTR201508001193368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201508001193368.